Improvement in symptoms in infants · GORD in infants
1 finding from 1 review
Adverse events ‐ not reported · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
pH indices ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic metrics ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in pH metrics in infants · GORD in infants
1 finding from 1 review
Endoscopic metrics ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in symptoms and signs in infants · GORD in infants
1 finding from 1 review
Clinical response at end of study (4 weeks) · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes clinical response at end of study (4 weeks) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty).
1 finding from 1 review
Quality of life at end of study (26 weeks) · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).
1 finding from 1 review
Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).
1 finding from 1 review
Treatment success as defined by the authors · children (4 to 18 years) with functional abdominal pain disorders
Probiotic may leads to higher treatment success (at study end, as reported by study authors) compared with placebo (low certainty).
1 finding from 1 review
Severity of pain (at study end, using the Faces Pain Scale) · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether synbiotic changes severity of pain (at study end, using the Faces Pain Scale) compared with placebo (very low certainty).
1 finding from 1 review
Pain frequency or change in pain frequency · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review